ライフサイエンスコーパス: goserelin

1 g daily 21 days after the first injection of goserelin.

2 tumor flare (16% v 3%) were more common with goserelin.

3 ents received combined ADT that consisted of goserelin 3.6 mg every 4 weeks and flutamide 250 mg tid

4 Patients were treated with goserelin 3.6 mg subcutaneous monthly and began anastroz

5 esia 5 weeks after endometrial thinning with goserelin 3.6 mg.

6 Men and premenopausal women also received goserelin (3.6 mg once every 28 days).

7 Patients were randomly assigned to goserelin (3.6 mg subcutaneously every 4 weeks; (n = 69)

8 ing 924 premenopausal patients to 2 years of goserelin (3.6 mg subcutaneously once every 28 days), ta

9 immediate antiandrogen therapy, with either goserelin, a synthetic agonist of gonadotropin-releasing

10 d 198 healthy men 20 to 50 years of age with goserelin acetate (to suppress endogenous testosterone a

11 After chemotherapy, goserelin acetate and bicalutamide were prescribed for 1

12 2b-T4 prostate cancer received flutamide and goserelin acetate for 4 months, with RT beginning at the

13 healthy men (20 to 50 years of age) received goserelin acetate to suppress endogenous production of g

14 Another 202 healthy men received goserelin acetate, placebo gel or testosterone gel, and

15 nety-eight healthy men, ages 20-50, received goserelin acetate, which suppresses endogenous gonadal s

16 djuvant endocrine therapy, she began monthly goserelin administration to achieve ovarian function sup

17 rial of men treated with or without adjuvant goserelin after radiation therapy (RT) for locally advan

18 ADT consisted of goserelin and bicalutamide for 2 years.

19 AF-Z), or CAF followed by 5 years of monthly goserelin and daily tamoxifen (CAF-ZT).

20 After two monthly treatments with goserelin and exemestane, a sensitive assay for serum es

21 All patients received 4 months of goserelin and flutamide before and during RT.

22 ion changes after 3 months of treatment with goserelin and flutamide.

23 Goserelin and ovariectomy resulted in similar FFS and OS

24 FFS and OS were similar for goserelin and ovariectomy.

25 Combined goserelin and tamoxifen therapy showed no benefit over s

26 amoxifen (40 mg orally once daily), combined goserelin and tamoxifen, or no adjuvant endocrine therap

27 served as controls and received placebos for goserelin and testosterone.

28 at 5 years, 84% of patients on the adjuvant goserelin arm and 71% on the observation arm remain with

29 r disease-free survival rate on the adjuvant goserelin arm is 53% versus 20% on the observation arm (

30 tuarial 5-year survival (66% on the adjuvant goserelin arm v 55% on the observation arm) reaches stat

31 us an AI (n = 2,552); patients also received goserelin as clinically indicated.

32 whereas genomic high-risk patients had early goserelin benefit.

33 il (CAF), CAF followed by 5 years of monthly goserelin (CAF-Z), or CAF followed by 5 years of monthly

34 elin group) or standard chemotherapy without goserelin (chemotherapy-alone group).

35 ally localized PCa were randomly assigned to goserelin combined with dutasteride (ZD), bicalutamide a

36 that treatment of prostate cancer cells with goserelin-conjugated gold nanorods (gGNRs) promotes gona

37 Participants were randomized to active (goserelin [GnRHa] 3.6 mg implant) or placebo interventio

38 standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy wit

39 .4% v 11.4% for men treated without adjuvant goserelin (Gray's P = .17).

40 ne group (21% vs. 11%, P=0.03); women in the goserelin group also had improved disease-free survival

41 data, the ovarian failure rate was 8% in the goserelin group and 22% in the chemotherapy-alone group

42 ted, pregnancy occurred in more women in the goserelin group than in the chemotherapy-alone group (21

43 hemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without gosere

44 ratio, 1.1315 [CI, 0.533 to 2.404]) than for goserelin (hazard ratio, 1.1172 [CI, 0.898 to 1.390]).

45 nd genomic high-risk patients (n = 158) from goserelin (HR, 0.24; 95% CI, 0.10 to 0.54).

46 ted a randomized phase III trial of adjuvant goserelin in definitively irradiated patients with carci

47 (short-term ADT [STAD] + RT) or 24 months of goserelin (long-term ADT [LTAD] + RT).

48 Goserelin lowered serum estradiol to postmenopausal leve

49 erapy (short-term [ST]AD-RT) or 24 months of goserelin (LTAD-RT); 1,554 patients were entered onto th

50 er were randomly assigned to RT and adjuvant goserelin or RT alone.

51 mone-releasing hormone agonists (leuprolide, goserelin, or triptorelin) use as a time-dependent varia

52 The goserelin/ovariectomy death hazards ratio was .80 and th

53 The combination of goserelin plus anastrozole has substantial antitumor act

54 ive patients (n = 584, median age 47 years), goserelin, tamoxifen, and the combination significantly

55 Significant goserelin-tamoxifen interaction was observed (P = .016).

56 ; P = .16; when censoring at time of salvage goserelin therapy, HR = 0.99; 95% CI, 0.58 to 1.69; P =

57 ere was no overall advantage for addition of goserelin to CAF.

58 es (GnRHa; nafarelin, leuprolide, buserelin, goserelin, triptorelin), laparoscopic ablation, and exci

59 ascular mortality for men receiving adjuvant goserelin was 8.4% v 11.4% for men treated without adjuv

60 Goserelin was safe and well tolerated.

61 eased risk from the addition of tamoxifen to goserelin was seen in genomic high-risk patients (HR, 3.

62 pretation of the findings, administration of goserelin with chemotherapy appeared to protect against